Covered recipient · General Payments record
MADELEINE E GANTZ
Allopathic & Osteopathic Physicians Dermatology
General Payments · PY2021–2024
$2,616.40
- Reported across 77 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $760.80 | 18 |
| Education | $79.99 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $477.00 | 13 |
| Galderma Laboratories, L.P. | $145.46 | 4 |
| MERZ NORTH AMERICA, INC. | $138.34 | 1 |
| SANOFI-AVENTIS U.S. LLC | $79.99 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (19)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $21.60 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103771754 | CMS |
| ABBVIE INC. | $22.68 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103771756 | CMS |
| ABBVIE INC. | $20.46 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103771758 | CMS |
| ABBVIE INC. | $144.05 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103771760 | CMS |
| ABBVIE INC. | $133.25 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103771762 | CMS |
| ABBVIE INC. | $23.05 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103771764 | CMS |
| ABBVIE INC. | $8.38 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103771766 | CMS |
| ABBVIE INC. | $22.37 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103771768 | CMS |
| ABBVIE INC. | $19.71 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103771770 | CMS |
| ABBVIE INC. | $7.80 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103771772 | CMS |
| ABBVIE INC. | $25.87 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103771774 | CMS |
| ABBVIE INC. | $8.06 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103771776 | CMS |
| ABBVIE INC. | $19.72 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103771778 | CMS |
| Galderma Laboratories, L.P. | $107.07 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145298722 | CMS |
| Galderma Laboratories, L.P. | $13.21 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145298724 | CMS |
| Galderma Laboratories, L.P. | $13.95 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145298726 | CMS |
| Galderma Laboratories, L.P. | $11.23 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145298728 | CMS |
| MERZ NORTH AMERICA, INC. | $138.34 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146372660 | CMS |
| SANOFI-AVENTIS U.S. LLC | $79.99 | 10/24/2024 | Education | Undisputed | 01/23/2026 | 1139913327 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.